Abstract: Provided herein are chimeric antigen receptors (CARs) comprising a truncated EGFRvIII (Ev3) in the hinge region of the CAR and/or a humanized scFv. Further provided herein are immune cells expressing the CARs as well as methods of their use in the treatment of immune disorders.

Abstract: Embodiments of the disclosure include methods and compositions in which NK cells are modified by the hand of man to express the T-cell receptor and CD3 co-receptor on NK cells that do not naturally express them. Such modified NK cells work effectively with bispecific or multi-specific antibodies that are tailored to comprise anti-CD3 antibodies that bind the modified NK cells, thereby triggering signaling, activation, and cytotoxicity of target cells to which the antibodies also bind. Thus, the NK cells are specifically configured to be able to work effectively with Bispecific NK cell engagers (BiKEs) as well as Bispecific T cell Engagers (BiTEs).

Abstract: Provided herein are chimeric antigen receptors (CARs) comprising a truncated EGFRvIII (Ev3) in the hinge region of the CAR and/or a humanized scFv. Further provided herein are immune cells expressing the CARs as well as methods of their use in the treatment of immune disorders.

Abstract: Provided herein are methods for expanding NK cells expressing chimeric antigen receptors and/or T cell receptors. Further provided are methods for treating diseases by administering the CAR NK cells.

Abstract: Provided herein are cryopreservation compositions and methods for cells of any kind, including for cells for adoptive cell therapy that are off-the-shelf cells. The cells for cryopreservation may be expanding NK cells expressing chimeric antigen receptors. In specific cases, the cryopreservation media comprises a cryoprotectant, such as DMSO, glycerol or hydroxyethol starch; serum or a non-serum alternative, such as platelet lysate; and one or more cytokines that are either natural, modified, synthetic, or recombinant.

Abstract: The present invention concerns methods of treating a disease such as leukemia in a subject by administering natural killer (NK) cells. In particular aspects, HLA-C1-licensed KIR2DL2/3 and KIR2DS2 NK cells are administered to a subject with an HLA-C genotype either homozygous or heterozygous for the C1 allele, or HLA-C2 licensed cells are administered to a subject with an HLA-C genotype homozygous for the C2 allele. In further aspects, the NK cells are genetically modified to express a chimeric antigen receptor and interleukin 15.

Abstract: Provided herein are chimeric antigen receptors (CARs) comprising a truncated EGFRvIII (Ev3) in the hinge region of the CAR and/or a humanized scFv. Further provided herein are immune cells expressing the CARs as well as methods of their use in the treatment of immune disorders.

Abstract: Provided herein are universal antigen presenting cells. Also provided herein are methods of expanding immune cells using the UAPCs and methods for the treatment of a disease, such as cancer, using the expanded immune cells.

Abstract: The present invention concerns methods of treating a disease such as leukemia in a subject by administering natural killer (NK) cells. In particular aspects, HLA-C1-licensed KIR2DL2/3 and KIR2DS2 NK cells are administered to a subject with an HLA-C genotype either homozygous or heterozygous for the C1 allele, or HLA-C2 licensed cells are administered to a subject with an HLA-C genotype homozygous for the C2 allele. In further aspects, the NK cells are genetically modified to express a chimeric antigen receptor and interleukin 15.